English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

New cyclohexylidene 1,2,4,5-tetraoxanes with polar guanidine and urea based   groups were synthesized and evaluated for antimalarial activity against   chloroquine resistant and susceptible Plasmodium falciparum strains.   Derivatives showed moderate nM range antimalarial activities and low   cytotoxicity. N-phenyl-urea derivative 24 exhibited best resistant indices   (RIW2 = 0.44, RITM91C235 = 0.80), and was not toxic against human normal   peripheral blood mononuclear cells (IC50 > 200 μM). Seven derivatives were   tested in vitro against four human cancer cell lines and they demonstrated   high selectivity toward leukemia K562 cells. One compound, derivative 21 with   a primary amino-group, was the first tetraoxane tested in vivo against   Toxoplasma gondii as another Apicomplexan parasite. Subcutaneous   administration at a dose of 10 mg/kg/day for 8 days allowed survival of 20 %   of infected mice, thus demonstrating the high potential of tetraoxanes for   the treatment of Apicomplexan parasites. [Projekat Ministarstva nauke   Republike Srbije, br. 172008 i br. 175011

Tetraoxanes as inhibitors of apicomplexan parasites Plasmodium falciparum and Toxoplasma gondii and anti-cancer molecules